Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
88 hedge funds and large institutions have $35.2M invested in Chinook Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 30 reducing their positions, and 18 closing their positions.
9% less funds holding
Funds holding: 97 → 88 (-9)
13% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 30
34% less capital invested
Capital invested by funds: $53.6M → $35.2M (-$18.4M)
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$1.34M |
| 2 |
Renaissance Technologies
New York
|
+$1.23M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$714K |
| 4 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$258K |
| 5 |
D.E. Shaw & Co
New York
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.71M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$1.49M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$381K |
| 4 |
ClearBridge Investments
New York
|
-$341K |
| 5 |
Goldman Sachs
New York
|
-$282K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$2K | -300 | Closed |
|
|
AG
102
Aperio Group
Sausalito,
California
| – | -$1K | -189 | Closed |
|
KDNY Hedge Fund Activity: Q3 2019 in Review
88 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2019, worth a combined $35.2M — down 34% from $53.6M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of KDNY and 9 opened new positions — a net loss of 9 holders — while 30 trimmed existing stakes and 26 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $1.34M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.71M sold.
- 88 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2019, down from 97 in Q2 2019.
- Funds reported $35.2M of Chinook Therapeutics, Inc. Common Stock stock for Q3 2019, down 34% quarter-over-quarter.
- 9 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2019 and 18 closed out, a net change of -9 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q3 2019 was BVF Inc, an estimated $1.34M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2019 was EcoR1 Capital, an estimated $2.71M sold.
Based on aggregated 13F filings for Q3 2019.